FOLH1 and prostate cancer: The diagnostic performance of radiolabeled PSMA PET/CT in patients with a biochemical recurrence (BCR) of prostate cancer (serum PSA greater than 0.2 ng/ml after prostatectomy or nadir PSA greater than 2 ng/ml after radiotherapy1) is well-established.